Home » Stocks » MorphoSys

MorphoSys AG (MOR)

Stock Price: $33.62 USD -0.80 (-2.32%)
Updated Jul 16, 2020 10:56 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 4.39B
Revenue (ttm) 309.43M
Net Income (ttm) 115.17M
Shares Out 130.66M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $33.62
Previous Close $34.42
Change ($) -0.80
Change (%) -2.32%
Day's Open 33.67
Day's Range 33.51 - 33.76
Day's Volume 23,301
52-Week Range 18.21 - 37.96

More Stats

Market Cap 4.39B
Enterprise Value 3.94B
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 130.66M
Float 126.81M
EPS (basic) -0.635
EPS (diluted) -0.26
FCF / Share 1.17
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 3.40%
Payout Ratio n/a
Shares Short 744,560
Short Ratio 8.30
Short % of Float n/a
Beta 1.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 29.40
PS Ratio 14.20
PB Ratio 5.52
Revenue 309.43M
Operating Income 119.13M
Net Income 115.17M
Free Cash Flow 149.40M
Net Cash 454.77M
Net Cash / Share 3.48
Gross Margin n/a
Operating Margin 38.50%
Profit Margin 37.20%
FCF Margin 48.28%
ROA 7.98%
ROE 20.29%
ROIC 22.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 7
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(9.64% upside)
Current: 33.62
Target: 36.86
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-6.13%14.45%34.27%-
Gross Profit59.6774.6566.7949.74
Operating Income-108-60.06-67.06-60.10
Net Income-103-56.17-69.83-60.38
Shares Outstanding31.6131.3428.9526.44
Earnings Per Share-0.82-0.45-0.60-0.57
Operating Cash Flow-80.14-33.27-38.45-46.62
Capital Expenditures-3.08-1.79-1.32-2.50
Free Cash Flow-83.22-35.06-39.76-49.11
Cash & Equivalents273359312280
Total Debt42.570.070.090.22
Net Cash / Debt230359312280
Book Value395488359415
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MorphoSys AG
Country Germany
Employees 516
CEO Jean-Paul Kress

Stock Information

Ticker Symbol MOR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MOR
IPO Date March 9, 1999


MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys' investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.